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Background: A 7.6 magnitude earthquake on April 25, 2015 in
Nepal followedby a series of aftershocks claimed almost 9,000 lives
and caused injuries among 23,000 people. Tribhuvan University
Teaching Hospital (TUTH), a tertiary care center, was one of the
major hospitals in Kathmandu providing care to the earthquake
victims. This study was conducted to identify etiological agents of
various infections among earthquake victims admitted to TUTH.
Methods & Materials: A total of 357 samples were received
from earthquake victims in the Microbiology laboratory of TUTH
from 25 April to 1 July, 2015. The samples included pus/swab
(n=130), blood (n=81), urine (n=77), sputum (n=47) and body ﬂuids
(n=22). These samples were received from emergency depart-
ment and inpatient wards including intensive care units. Standard
methodology were followed to identify the microorganisms and
susceptibilities were done using disk diffusion method.
Results: Microbial growth was seen in 67.7% of pus, 18.2%
of body ﬂuid and 13.6% of blood samples. Similarly, signiﬁcant
growth was found in 48.9% of sputum and 28.6% of urine sam-
ples. Mixed growth of microorganisms was seen in 20.8% of pus, of
which combined growth of Staphylococcus aureus and Escherichia
coli was most common (n=3). Escherichia coli was the most com-
mon isolate from pus (n=26), followed by Staphylococcus aureus
(n=18) and Acinetobacter calcoaceticus baumannii (Acb) complex
(n=17). Escherichia coli (n=11) was the predominant isolate from
urine samples. In sputum samples, Klebsiella pneumoniae (n=7)
was most common followed by Escherichia coli (n=4) and Pseu-
domonas aeruginosa (n=4). In blood cultures, Citrobacter freundii
(n=3) and Burkholderia cepacia complex (n=3) were the common
isolates. Escherichia coli, Klebsiella pneumoniae and Acb complex
were isolated from different body ﬂuid samples. Out of total 140
gram-negative bacterial isolates, 56.4% (n=79) were carbapenem
resistant. Similarly, methicillin resistance was seen in 23.8% (n=5)
of total 21 Staphylococcus aureus isolates.
Conclusion: Based on the specimens received by Microbiology
laboratory, pus followed by blood and urine were the most com-
mon samples received andwound related infectionswere themost
common type of infection among the earthquake victims. A variety
of bacteria was isolated from these samples including a signiﬁcant
number of carbapenem-resistant gram negative bacilli.
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Background: Acquaintance is scanty on PQ efﬁcacy and P. vivax
relapse in Udupi district, Karnataka, India. We assessed the efﬁ-
cacy of 14 days PQ treatment for preventing recurrence of P. vivax
infection.
Methods & Materials: Microscopy and PCR proven P. vivax
infected adults (≥18 years) from one tertiary and ﬁve primary
health centres, pre-enrolled in a chloroquine-primaquine (CQ-PQ)
combined therapeutic trial, upon convalescence on 28th day were
requested to participate in another 15 months long follow up
study. Participantswere treated previouslywith CQ 25mg/kg body
weight over 3 days and PQ 0.25 mg/kg body weight daily for 2
weeks upon conﬁrmation of G6PD levels. A complete adherence
for the prescribed CQ-PQ regimens was noted. A peripheral blood
smear examination was performed with every participant within
1–2 months duration. A positive P. vivax case was considered as
relapse/reinfection and retreated with CQ-PQ. Data were analysed
by independent t-test or Mann Whitney U test, 2 test or Fisher’s
exact test and Cox regression using SPSS v15.0, South Asia, Banga-
lore, India.
Results: Of total 323participants in CQ-PQ therapeutic trial, 114
participated in 15months long followup study. Of 114participants,
28 (24.56%) recurred subsequently, including twoparticipantswith
two recurrences and one participant with three recurrences. One
patient did present with P. falciparum malaria after 3 months. The
median duration of ﬁrst recurrence was 3.14 months (IQR, 2.23 –
6.03) which ranged from 1.22 to 15.07 months. There were no clin-
ical dissimilarities (p>0.05) among recurrence and non-recurrence
groups. Participants with past history of P. vivax malaria had sig-
niﬁcantly higher odds of recurrence [HR (95% CI): 2.62 (1.24-5.54),
p = 0.012]. The severity of disease (11.40%, 13/114) was not associ-
ated (p=1.00)with recurrence. Of 28 recurrent cases, 3 (10.71%) had
severe malaria initially, however, none developed severe malaria
during recurrences.
Conclusion: Despite complete adherence to 14 days PQ reg-
imen, P. vivax results in substantial recurrences in Udupi taluk.
Further, molecular investigations are required to determine
the true relapse/reinfection proportion and their determinants.
Patients with past history of P. vivax malaria are at high risk of
recurrences.
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